Sillajen will start recruiting patients for the first phase clinical trial of a new oncology drug, the pharmaceutical company said Tuesday. This is Sillajen's first major project since it was allowed to resume stock trading in October.
At least in this industry, “this will work for sure” and “it is certain this time” should not be used or trusted.
Scandal-ridden bio firm Sillajen surged 29.47 percent from its opening price of 8,380 won ($5.90) to 10,850 won on Thursday. The company resumed stock trading the same day on Kosdaq after a two-and-a-half year suspension ...
Retail investors in Kosdaq-listed biopharmaceutical companies are losing their shirts after a series of scandals, and at least one company faces possible delisting.
Korea Exchange on Tuesday tentatively delisted scandal-ridden Sillajen from the Kosdaq.
SillaJen, once the Kosdaq’s second largest company, has been given one year by the Korea Exchange to get its act together.
Seoul prosecutors said Monday they were unable to find evidence that political officials had any illegal involvement with an ongoing criminal investigation into SillaJen, which has led to charges against multiple company officials.
SillaJen CEO Moon Eun-sang was arrested Tuesday on insider trading charges, after he allegedly sold millions of shares in the biopharmaceutical company just before a failed clinical trial caused the stock price to tank in August.
Korea JoongAng Daily Sitemap
